查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1662875

抗疟疾药市场预测至 2030 年：按药物类型、药物类别、疟疾类型、给药方式、分销管道、最终用户和地区进行的全球分析

Anti-Malarial Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, Drug Class, Malaria Type, Mode of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球抗疟疾药市场预计在 2024 年达到 10.441 亿美元，到 2030 年预计将达到 14.396 亿美元，预测期内的复合年增长率为 5.5%。

抗疟疾药是用于预防或治疗疟疾原虫引起的寄生虫感染疾病的药物。这些药物针对的是人体内处于生命週期不同阶段的寄生虫。常见的抗疟疾药包括Chloroquine、奎宁和青蒿素为基础的联合治疗（ACT）。它们透过抑制红血球内寄生虫的生长、复製和存活发挥作用。抗疟疾药在疟疾流行地区至关重要，疟疾是主要的公共卫生威胁。它也用于防止旅行者前往高风险地区。

根据2021年12月发布的最新《世界疟疾报告》，2020年全球估计有2.41亿例疟疾病例，导致6.27亿人死亡。这意味着与 2019 年相比，2020 年的病例增加了约 1,400 万例，死亡人数增加了 69,000 人。

医疗支出增加

疟疾发病率上升和有效治疗需求增加推动了市场医疗保健支出的增加。各国政府和组织正在拨出更多资金用于疟疾控制，并致力于改善疟疾流行地区获得这些药物的机会。不断加强的研究和开发以及对创新解决方案的需求有助于开发市场，确保全球范围内更好的医疗保健基础设施和更有效的治疗。

可用性和可负担性

抗疟疾药的供应和负担能力可能会对市场产生严重的负面影响。在经济困难地区，高昂的药物成本和不足的卫生基础设施阻碍了及时治疗，导致疟疾相关死亡率上升。此外，无法持续获得药物会导致抗药性，使治疗结果变得复杂。这些差异加剧了公共卫生危机，特别是在低收入和偏远地区，阻碍了控制疟疾的进展，并阻碍了整体市场的成长。

疟疾盛行率高

疟疾的高发性对市场产生了重大影响，推动了对有效治疗的需求。治疗总是需要的，特别是在疟疾负担较重的地区，例如撒哈拉以南非洲和东南亚。患者数量的不断增长促使政府和卫生组织对药品供应、研究和分销进行投资。这种需求，加上对现有治疗方法的抵制日益增加，进一步推动了市场成长。

认识和教育有限

对于疟疾及其治疗的认识和教育有限可能会对市场产生负面影响。缺乏知识可能导致不当使用药物，从而产生抗药性和降低疗效。对预防方法缺乏了解可能会导致治疗延误和传播率增加。缺乏教育阻碍了对所需药物的需求，减缓了疟疾控制工作，并抑制了市场成长，尤其是在农村和偏远地区。

COVID-19 的影响

新冠肺炎疫情分散了人们对疟疾控制的资源和注意力，扰乱了市场。供应链中断、卫生系统紧张以及疟疾流行地区药品取得有限，导致治疗延误。此外，这次疫情也引发了人们对某些抗疟疾药对抗新冠肺炎有效性的争论和困惑，影响了疟疾患者对这些药物的可近性。这对疟疾治疗整体和市场稳定产生了负面影响。

预计奎宁部分将在预测期内占据最大的市场占有率

预计预测期内奎宁将占据最大的市场占有率。奎宁仍然是市面上重要的抗疟疾药，尤其是在治疗严重疟疾的情况下。奎宁取自金鸡纳树皮，已被使用了几个世纪。儘管出现了新药，奎宁仍然被广泛使用，特别是在抗药性普遍存在的地区。由于其经济实惠和有效性，它成为一种必不可少的治疗方法，尤其是在一线治疗失败或在无法获得先进疗法的地区。

预计预测期内医院部门将以最高的复合年增长率成长。

预计预测期内医院部门将呈现最高的成长率。该医院是抗疟疾药的重要分销点，提供住院和门诊治疗。医院透过提供正确的诊断和管理有效的药物治疗方案（包括奎宁和较新的治疗方法）为市场成长做出了贡献。他们在疟疾流行地区发挥至关重要的作用，帮助控制疫情、教育患者并改善整体治疗机会。

比最大的地区

在预测期内，由于疟疾盛行率较低，预计北美将占据最大的市场占有率。但对于旅行者、军事相关人员和管理输入病例的卫生专业人员来说，它仍然很重要。北美製药公司生产抗疟疾药，服务全球市场，并专注于抗药性和创新治疗方法的研究。各国政府也支持疟疾流行国家的消除疟疾倡议，间接影响当地的市场动态。

复合年增长率最高的地区

预计预测期内亚太地区将呈现最高的复合年增长率。印度、中国和印尼等国家每年报告大量疟疾病例，需要有效的抗疟治疗。不断努力开发新的药物组合和配方正在促进市场的扩大。此外，这些国家人口众多，疟疾发生率高，是市场的主要贡献者。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球抗疟疾药市场按药物类型划分

  • 介绍
  • Chloroquine
  • 奎宁
  • 青蒿素联合治疗（ACT）
  • 甲氟喹
  • 伯氨喹
  • 其他药物类型

6. 全球抗疟疾药市场依药物类别划分

  • 介绍
  • 青蒿素
  • 抗叶酸
  • 金鸡纳生物碱
  • 阿托伐醌-氯胍

7. 全球抗疟疾药市场依疟疾类型划分

  • 介绍
  • 疟疾原虫疟原虫
  • 疟疾原虫
  • 疟疾原虫
  • 疟疾原虫疟原虫

8. 全球抗疟疾药市场依给药方式划分

  • 介绍
  • 口服
  • 注射/静脉注射
  • 局部的

9. 全球抗疟疾药市场依通路划分

  • 介绍
  • 政府和非政府组织项目
  • 零售药局
  • 网路药局

第 10 章 全球抗疟疾药市场（依最终用户划分）

  • 介绍
  • 医院
  • 诊所和健康中心
  • 居家医疗
  • 其他的

第 11 章 全球抗疟疾药市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Novartis
  • Sanofi
  • GlaxoSmithKline
  • Bayer
  • Cipla
  • Mylan
  • Merck & Co.
  • Lupin Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Sumitomo Dainippon Pharma
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Hetero Healthcare
  • Bharat BIoTech
  • Takeda Pharmaceutical Company
  • Bausch Health
Product Code: SMRC28737

According to Stratistics MRC, the Global Anti-Malarial Drugs Market is accounted for $1044.1 million in 2024 and is expected to reach $1439.6 million by 2030 growing at a CAGR of 5.5% during the forecast period. Anti-Malarial Drugs are medications used to prevent or treat malaria, a parasitic infection caused by Plasmodium species. These drugs target the parasite at various stages of its lifecycle in the human body. Common anti-malarials include chloroquine, quinine, and artemisinin-based combination therapies (ACTs). They work by inhibiting parasite growth, replication, or survival within red blood cells. Anti-Malarial Drugs are crucial in malaria-endemic regions, where the disease poses a significant public health threat. They are also used for prophylaxis in travelers visiting high-risk areas.

According to the latest World Malaria Report, released in December 2021, there were an estimated 241 million cases of malaria and 627,000 resulting deaths worldwide in 2020. This represents about 14 million more cases in 2020 compared to 2019, and 69,000 more deaths.

Market Dynamics:

Driver:

Increasing healthcare expenditure

The increasing healthcare expenditure in the market is driven by rising malaria incidences and the growing demand for effective treatments. Governments and organizations are allocating more funds to combat malaria, focusing on improving access to these drugs in endemic regions. Enhanced research and development efforts, along with the need for innovative solutions, contribute to expanding the market, ensuring better healthcare infrastructure and more effective treatments worldwide.

Restraint:

Accessibility and affordability

Limited accessibility and affordability of Anti-Malarial Drugs can have severe negative effects on the market. In regions with economic challenges, high drug costs and inadequate healthcare infrastructure hinder timely treatment, leading to increased malaria-related mortality. Inconsistent access also fosters drug resistance, complicating treatment effectiveness. This disparity exacerbates public health crises, particularly in low-income and remote areas, preventing progress in controlling malaria and impeding overall market growth.

Opportunity:

High prevalence of malaria

The high prevalence of malaria significantly impacts the market, driving demand for effective treatments. Regions with a high burden of malaria, especially in sub-Saharan Africa and Southeast Asia, experience constant need for these drugs. The increasing number of cases prompts governments and health organizations to invest in drug accessibility, research, and distribution. This demand, coupled with rising resistance to existing treatments, further fuels market growth.

Threat:

Limited awareness and education

Limited awareness and education about malaria and its treatment can negatively impact the market. Lack of knowledge leads to improper use of drugs, contributing to resistance and reduced effectiveness. Inadequate understanding of prevention methods results in delayed treatment and higher transmission rates. This lack of education, especially in rural or remote areas, hinders demand for necessary drugs, slowing efforts to control malaria and impeding market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by diverting resources and attention away from malaria control efforts. Supply chain interruptions, healthcare system strain, and limited access to drugs in malaria-endemic regions resulted in delays in treatment. Additionally, the pandemic sparked debates over the efficacy of certain Anti-Malarial Drugs for COVID-19, creating confusion and affecting their availability for malaria patients. This negatively impacted overall malaria treatment and market stability.

The quinine segment is expected to be the largest market share during the forecast period

The quinine segment is expected to account for the largest market share during the forecast period. Quinine remains a crucial anti-malarial drug in the market, particularly in severe cases of malaria. It is derived from the bark of the cinchona tree and has been used for centuries. Despite the emergence of newer drugs, quinine is still widely prescribed, especially in regions with drug resistance. Its affordability and effectiveness make it an essential treatment, especially when first-line therapies fail or in areas with limited access to advanced medications.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate. They are key distribution points for anti-malarial medications, offering both inpatient and outpatient care. Hospitals contribute to market growth by ensuring proper diagnosis and administering effective drug regimens, including quinine and newer therapies. Their role is critical in malaria-endemic regions, where they help manage outbreaks, educate patients, and improve overall treatment access.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to the region's low malaria prevalence. However, it remains significant for travelers, military personnel, and healthcare professionals managing imported cases. North American pharmaceutical companies contribute to the global market by producing Anti-Malarial Drugs, and research focuses on drug resistance and innovative treatments. Governments also support malaria eradication initiatives in endemic countries, indirectly affecting the regional market dynamics.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Countries such as India, China, and Indonesia report a substantial number of malaria cases annually, necessitating effective anti-malarial treatments. Ongoing initiatives to develop new drug combinations and formulations are contributing to market expansion. Additionally, These countries are major contributors to the market due to their large populations and high malaria incidence rates.

Key players in the market

Some of the key players in Anti-Malarial Drugs market include Novartis, Sanofi, GlaxoSmithKline, Bayer, Cipla, Mylan, Merck & Co., Lupin Pharmaceuticals, Teva Pharmaceutical Industries, Sumitomo Dainippon Pharma, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero Healthcare, Bharat Biotech, Takeda Pharmaceutical Company and Bausch Health.

Key Developments:

In December 2024, Aurobindo Pharma Ltd said its step-down subsidiary CuraTeQ Biologics s.r.o. has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its biosimilar version of bevacizumab..

In April 2024, Novartis and Medicines for Malaria Venture (MMV) announced positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem(R) (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety.

Drug Types Covered:

  • Chloroquine
  • Quinine
  • Artemisinin-Based Combination Therapies (ACTs)
  • Mefloquine
  • Primaquine
  • Other Drug Types

Drug Classes Covered:

  • Artemisinin
  • Antifolate Drugs
  • Cinchona Alkaloids
  • Atovaquone-Proguanil

Malaria Types Covered:

  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Plasmodium Malaria
  • Plasmodium Ovale

Mode of Administrations Covered:

  • Oral
  • Injectable/Intravenous
  • Topical

Distribution Channels Covered:

  • Government & NGO Programs
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Clinics and Health Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anti-malarial Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Chloroquine
  • 5.3 Quinine
  • 5.4 Artemisinin-Based Combination Therapies (ACTs)
  • 5.5 Mefloquine
  • 5.6 Primaquine
  • 5.7 Other Drug Types

6 Global Anti-malarial Drugs Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Artemisinin
  • 6.3 Antifolate Drugs
  • 6.4 Cinchona Alkaloids
  • 6.5 Atovaquone-Proguanil

7 Global Anti-malarial Drugs Market, By Malaria Type

  • 7.1 Introduction
  • 7.2 Plasmodium Falciparum
  • 7.3 Plasmodium Vivax
  • 7.4 Plasmodium Malaria
  • 7.5 Plasmodium Ovale

8 Global Anti-malarial Drugs Market, By Mode of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Injectable/Intravenous
  • 8.4 Topical

9 Global Anti-malarial Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Government & NGO Programs
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Anti-malarial Drugs Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics and Health Centers
  • 10.4 Home Care Settings
  • 10.5 Other End Users

11 Global Anti-malarial Drugs Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novartis
  • 13.2 Sanofi
  • 13.3 GlaxoSmithKline
  • 13.4 Bayer
  • 13.5 Cipla
  • 13.6 Mylan
  • 13.7 Merck & Co.
  • 13.8 Lupin Pharmaceuticals
  • 13.9 Teva Pharmaceutical Industries
  • 13.10 Sumitomo Dainippon Pharma
  • 13.13 Aurobindo Pharma
  • 13.12 Dr. Reddy's Laboratories
  • 13.13 Hetero Healthcare
  • 13.14 Bharat Biotech
  • 13.15 Takeda Pharmaceutical Company
  • 13.16 Bausch Health

List of Tables

  • Table 1 Global Anti-malarial Drugs Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Anti-malarial Drugs Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 3 Global Anti-malarial Drugs Market Outlook, By Chloroquine (2022-2030) ($MN)
  • Table 4 Global Anti-malarial Drugs Market Outlook, By Quinine (2022-2030) ($MN)
  • Table 5 Global Anti-malarial Drugs Market Outlook, By Artemisinin-Based Combination Therapies (ACTs) (2022-2030) ($MN)
  • Table 6 Global Anti-malarial Drugs Market Outlook, By Mefloquine (2022-2030) ($MN)
  • Table 7 Global Anti-malarial Drugs Market Outlook, By Primaquine (2022-2030) ($MN)
  • Table 8 Global Anti-malarial Drugs Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 9 Global Anti-malarial Drugs Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 10 Global Anti-malarial Drugs Market Outlook, By Artemisinin (2022-2030) ($MN)
  • Table 11 Global Anti-malarial Drugs Market Outlook, By Antifolate Drugs (2022-2030) ($MN)
  • Table 12 Global Anti-malarial Drugs Market Outlook, By Cinchona Alkaloids (2022-2030) ($MN)
  • Table 13 Global Anti-malarial Drugs Market Outlook, By Atovaquone-Proguanil (2022-2030) ($MN)
  • Table 14 Global Anti-malarial Drugs Market Outlook, By Malaria Type (2022-2030) ($MN)
  • Table 15 Global Anti-malarial Drugs Market Outlook, By Plasmodium Falciparum (2022-2030) ($MN)
  • Table 16 Global Anti-malarial Drugs Market Outlook, By Plasmodium Vivax (2022-2030) ($MN)
  • Table 17 Global Anti-malarial Drugs Market Outlook, By Plasmodium Malaria (2022-2030) ($MN)
  • Table 18 Global Anti-malarial Drugs Market Outlook, By Plasmodium Ovale (2022-2030) ($MN)
  • Table 19 Global Anti-malarial Drugs Market Outlook, By Mode of Administration (2022-2030) ($MN)
  • Table 20 Global Anti-malarial Drugs Market Outlook, By Oral (2022-2030) ($MN)
  • Table 21 Global Anti-malarial Drugs Market Outlook, By Injectable/Intravenous (2022-2030) ($MN)
  • Table 22 Global Anti-malarial Drugs Market Outlook, By Topical (2022-2030) ($MN)
  • Table 23 Global Anti-malarial Drugs Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 24 Global Anti-malarial Drugs Market Outlook, By Government & NGO Programs (2022-2030) ($MN)
  • Table 25 Global Anti-malarial Drugs Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 26 Global Anti-malarial Drugs Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 27 Global Anti-malarial Drugs Market Outlook, By End User (2022-2030) ($MN)
  • Table 28 Global Anti-malarial Drugs Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 29 Global Anti-malarial Drugs Market Outlook, By Clinics and Health Centers (2022-2030) ($MN)
  • Table 30 Global Anti-malarial Drugs Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 31 Global Anti-malarial Drugs Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.